articleTop 1% cited
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Bone · 2008 · Vol. 43(2) · pp. 222–229
Paul D. Miller✉(Colorado Center for Bone Research)Michael A. BologneseE. Michael Lewiecki(New Mexico Clinical Research & Osteoporosis Center)Michael R. McClung(Bone Health and Osteoporosis Foundation)Beiying Ding(Amgen (United States))Matthew Austin(Amgen (United States))Yu Liu(Amgen (United States))Javier San Martín(Amgen (United States))
Bone Metabolism and DiseasesBone health and treatmentsBone health and osteoporosis researchDenosumabMedicineBone remodelingBone mineralOsteoporosisPlaceboDiscontinuationUrologyInternal medicineSurgery
MeSH terms
DenosumabAntibodies, MonoclonalBone and BonesDemographyFemaleHumansMiddle AgedOrgan SizeTime FactorsBiomarkersBone DensitySingle-Blind MethodTreatment OutcomePostmenopauseAlendronate
Funding
- Amgen
Citations
567
FWCI
20.83
field-weighted impact
References
42
Percentile
100%
vs. same field & year
Citations per year
Cited by
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Journal of Bone and Mineral Research · 2017 · 687 citations
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
Journal of Bone and Mineral Research · 2014 · 1,324 citations
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Journal of Bone and Mineral Research · 2008 · 598 citations
Denosumab and bisphosphonates: Different mechanisms of action and effects
Bone · 2010 · 701 citations
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Journal of Bone and Mineral Research · 2011 · 692 citations
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS
Bone · 2017 · 481 citations
References
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density
Cell · 1997 · 5,099 citations
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation
Cell · 1998 · 5,439 citations
Biochemical Markers of Bone Turnover, Endogenous Hormones and the Risk of Fractures in Postmenopausal Women: The OFELY Study
Journal of Bone and Mineral Research · 2000 · 716 citations
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
Proceedings of the National Academy of Sciences · 1998 · 4,244 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.